focus -WSS

focus

author：focus 2025-09-27 10:03:00 - browse：1116

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Scrutiny of post

leisure time

WSS

Malaria cases in Florida and Texas: Here’s what you need to know

Cue Health, Covid

Investigation reveals sickle cell patients pressured into sterilizations

In age of alternative facts, a scholarly course on calling out crap

Affirmative action in medical school literally saved lives

Tori Bowie and the unacceptable rates of Black maternal death

knowledge

focus

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Continuity nursing helped my family in our darkest PICU moments

Hollywood unions extend contract negotiations for actors

Making the case for fair compensation in clinical trials

Anesthesiologist group: stop taking Ozempic before surgery

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Drug repurposing or repositioning? The language matters

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cancer drug shortages should be causing more outrage

Listen: A conversation with researcher Kevin Esvelt on biosecurity

entertainment

How one medical school became remarkably diverse

Activists slam private health insurers over coverage restrictions

Eyeing GLP

FDA poised to publish guidelines for clinical trial diversity

Novavax promises a turnaround & Lilly roils the obesity market

BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

knowledge

hotspot

hotspot